➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Express Scripts
AstraZeneca
Dow
Johnson and Johnson

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Patent: 9,850,473

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 9,850,473
Title:Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from Streptococcus pneumoniae
Abstract: The present invention provides for recombinant Endo-D and selected mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor by transglycosylation. Such recombinant Endo-D and selected mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain.
Inventor(s): Wang; Lai-Xi (Ellicott City, MD)
Assignee: University of Maryland, Baltimore (Baltimore, MA)
Application Number:14/878,089
Patent Claims:see list of patent claims

Details for Patent 9,850,473

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline NUCALA mepolizumab INJECTABLE;SUBCUTANEOUS 761122 2019-06-06 ⤷  Free Forever Trial University of Maryland, Baltimore (Baltimore, MA) 2031-03-03 RX search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 2019-02-28 ⤷  Free Forever Trial University of Maryland, Baltimore (Baltimore, MA) 2031-03-03 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 2017-06-22 ⤷  Free Forever Trial University of Maryland, Baltimore (Baltimore, MA) 2031-03-03 RX Orphan search
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin VIAL;SINGLE-DOSE 761060 2018-04-09 ⤷  Free Forever Trial University of Maryland, Baltimore (Baltimore, MA) 2031-03-03 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
AstraZeneca
Express Scripts
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.